Canadian Cancer Trials Group Queen's University, Kitchener, Canada.
Ontario Institute for Cancer Research, Toronto, Canada.
J Clin Oncol. 2024 Aug 20;42(24):2887-2898. doi: 10.1200/JCO.24.00835. Epub 2024 Jun 2.
ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes.
MA.27 (ClinicalTrials.gov identifier: NCT00066573) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤-1; (-1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance < .05.
Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS ( < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated ( = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS ( = .001) in models with ER.
Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤-1.
ASCO/美国病理学家学会指南建议将雌激素受体(ER)和孕激素受体(PgR)的表达结果报告为阳性(1%-100%)。经统计学标准化的阳性定量可能表明阳性与乳腺癌结局的相关性存在差异。
MA.27(临床试验注册号:NCT00066573)是一项比较依西美坦与阿那曲唑在绝经后早期乳腺癌患者中的辅助治疗的 III 期临床试验。免疫组织化学 ER 和 PgR 的 HSCORE 和阳性率(%+)通过机器图像定量进行中心评估,并在 Box-Cox 方差稳定转换后进行统计学标准化,转换后 ER 的平方的平均值为 0,标准差(SD)为 1;对于 PgR,(1)自然对数(将 0 HSCORE 和 0%+增加 0.1)和(2)平方根。我们的主要终点是 MA.27 中位随访 4.1 年后的远处无病生存(DDFS),次要终点是无事件生存(EFS)。使用平均 0 左右标准差的截断点(≤-1;(-1,0];(0,1];>1)描述单变量生存,并使用 Kaplan-Meier 图进行检查,并使用 Wilcoxon(Peto-Prentice)检验统计量进行检查。调整后的 Cox 多变量回归有双侧 Wald 检验和名义显著性 <.05。
共入组 7576 例女性,其中 3048 例女性的肿瘤具有机器定量图像分析结果:ER 为 2900 例(95%),PgR 为 2726 例(89%),ER 和 PgR 均为 2582 例(3048 例的 85%)。更高的统计学标准化 ER 和 PgR HSCORE 和%+与更好的单变量 DDFS 和 EFS 相关(<.001)。在多变量评估中,ER HSCORE 和%+与 DDFS 无显著相关性(=.52-.88),而在包含 PgR 的模型中,较高的 PgR HSCORE 和%+与更好的 DDFS 显著相关(=.001)。
辅助统计学标准化区分了 ER 和 PgR 的定量水平。与 HSCORE 和%+≤-1 的患者相比,具有更高的 ER 和 PgR 标准化单位的患者具有更好的 DDFS。